Biomarkers of radiation exposure: Can they predict normal tissue radiosensitivity?

Clinical Oncology

Volumn 25, Issue 10, 2013, Pages 610-616

  Chua, M L K ^a,b   Rothkamm, K ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Chromosome aberrations; DNA damage response; Gamma H2AX foci; Normal tissue damage; Radiosensitivity; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER;

ADVERSE OUTCOME; ARTICLE; DNA DAMAGE; EXCISION REPAIR; GENOMICS; GENOTYPE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIATION DOSE ESCALATION; RADIATION EXPOSURE; RADIOSENSITIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE REACTION; TISSUES; VALIDITY;

CHROMOSOME ABERRATIONS; DNA DAMAGE RESPONSE; GAMMA-H2AX FOCI; NORMAL TISSUE DAMAGE; RADIOSENSITIVITY; RADIOTHERAPY;

BIOLOGICAL MARKERS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE;

EID: 84883275812     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.06.010     Document Type: Article

References (73)

1. Burnet N.G., Wurm R., Nyman J., Peacock J.H. Normal tissue radiosensitivity - how important is it?. Clin Oncol 1996, 8:25-34.
2. Abadir R., Hakami N. Ataxia telangiectasia with cancer. An indication for reduced radiotherapy and chemotherapy doses. Br J Radiol 1983, 56(665):343-345.
3. Hart R.M., Kimler B.F., Evans R.G., Park C.H. Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia telangiectasia. Int J Radiat Oncol Biol Phys 1987, 13:1237-1240.
4. Tucker S.L., Geara F.B., Peters L.J., Brock W.A. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity?. Radiother Oncol 1996, 38:103-113.
5. Burnet N.G., Nyman J., Turesson I., Wurm R., Yarnold J.R., Peacock J.H. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity. Lancet 1992, 339(8809):1570-1571.
6. Burnet N.G., Nyman J., Turesson I., Wurm R., Yarnold J.R., Peacock J.H. The relationship between cellular radiation sensitivity and tissue response may provide the basis for individualising radiotherapy schedules. Radiother Oncol 1994, 33:228-238.
7. Burnet N.G., Wurm R., Peacock J.H. Low dose-rate fibroblast radiosensitivity and the prediction of patient response to radiotherapy. Int J Radiat Biol 1996, 70:289-300.
8. Geara F.B., Peters L.J., Ang K.K., Wike J.L., Brock W.A. Prospective comparison of invitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 1993, 27:1173-1179.
9. Johansen J., Bentzen S.M., Overgaard J., Overgaard M. Evidence for a positive correlation between invitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Biol 1994, 66:407-412.
10. Brock W.A., Tucker S.L., Geara F.B., et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 1995, 32:1371-1379.
11. West C.M., Elyan S.A., Berry P., Cowan R., Scott D. Acomparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. Int J Radiat Biol 1995, 68:197-203.
12. Grote S.J., Joshi G.P., Revell S.H., Shaw C.A. Observations of radiation-induced chromosome fragment loss in live mammalian cells in culture, and its effect on colony-forming ability. Int J Radiat Biol 1981, 39:395-408.
13. Joshi G.P., Nelson W.J., Revell S.H., Shaw C.A. X-ray-induced chromosome damage in live mammalian cells, and improved measurements of its effects on their colony-forming ability. Int J Radiat Biol 1982, 41:161-181.
14. Borgmann K., Röper B., El-Awady R., et al. Indicators of late normal tissue response after radiotherapy for head and neck cancer: fibroblasts, lymphocytes, genetics, DNA repair, and chromosome aberrations. Radiother Oncol 2002, 64:141-152.
15. Borgmann K., Hoeller U., Nowack S., et al. Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy. Int J Radiat Oncol Biol Phys 2008, 71:256-264.
16. Hoeller U., Borgmann K., Bonacker M., et al. Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol 2003, 69:137-144.
17. Kühne M., Riballo E., Rief N., Rothkamm K., Jeggo P.A., Löbrich M. Adouble-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 2004, 64:500-508.
18. Wurm R., Burnet N.G., Duggal N., Yarnold J.R., Peacock J.H. Cellular radiosensitivity and DNA damage in primary human fibroblasts. Int J Radiat Oncol Biol Phys 1994, 30:625-633.
19. Kiltie A.E., Orton C.J., Ryan A.J., et al. Acorrelation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. Int J Radiat Oncol Biol Phys 1997, 39:1137-1144.
20. Zhou P.K., Sproston A.R., Marples B., West C.M., Margison G.P., Hendry J.H. The radiosensitivity of human fibroblast cell lines correlates with residual levels of DNA double-strand breaks. Radiother Oncol 1998, 47:271-276.
21. Dikomey E., Brammer I. Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose rates and plating conditions in a normal human fibroblast line. Int J Radiat Biol 2000, 76:773-781.
22. Kiltie A.E., Ryan A.J., Swindell R., et al. Acorrelation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. Radiother Oncol 1999, 51:55-65.
23. Rübe C.E., Fricke A., Schneider R., et al. DNA repair alterations in children with pediatric malignancies: novel opportunities to identify patients at risk for high-grade toxicities. Int J Radiat Oncol Biol Phys 2010, 78:359-369.
24. Vasireddy R.S., Sprung C.N., Cempaka N.L., Chao M., McKay M.J. H2AX phosphorylation screen of cells from radiosensitive cancer patients reveals a novel DNA double-strand break repair cellular phenotype. Br J Cancer 2010, 102:1511-1518.
25. Rübe C.E., Grudzenski S., Kühne M., et al. DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: implications for radiosensitivity testing. Clin Cancer Res 2008, 14:6546-6555.
26. Bhogal N., Kaspler P., Jalali F., et al. Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity invivo. Radiat Res 2010, 173:1-9.
27. Bourton E.C., Plowman P.N., Smith D., Arlett C.F., Parris C.N. Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment. Int J Cancer 2011, 129:2928-2934.
28. Chua M.L., Somaiah N., A'Hern R., et al. Residual DNA and chromosomal damage in exvivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Radiother Oncol 2011, 99:362-366.
29. Johansen J., Bentzen S.M., Overgaard J., Overgaard M. Relationship between the invitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol 1996, 40:101-109.
30. Peacock J., Ashton A., Bliss J., et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 2000, 55:173-178.
31. Kiltie A.E., Barber J.B., Swindell R., et al. Lack of correlation between residual radiation-induced DNA damage in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients. Int J Radiat Oncol Biol Phys 1999, 43:481-487.
32. Olive P.L., Banáth J.P., Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes invitro and its relation to late effects after prostate brachytherapy. Radiother Oncol 2008, 86:336-346.
33. Russell N.S., Begg A.C. Editorial radiotherapy and oncology 2002: predictive assays for normal tissue damage. Radiother Oncol 2002, 64:125-129.
34. Jung H., Beck-Bornholdt H.P., Svoboda V., Alberti W., Herrmann T. Quantification of late complications after radiation therapy. Radiother Oncol 2001, 61:233-246.
35. Burnet N.G., Johansen J., Turesson I., Nyman J., Peacock J.H. Describing patients'* normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int J Cancer 1998, 79:606-613.
36. Dikomey E., Borgmann K., Peacock J., Jung H. Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys 2003, 56:1194-1200.
37. Smith K.C., Hahn G.M., Hoppe R.T., Earle J.D. Radiosensitivity invitro of human fibroblasts derived from patients with a severe skin reaction to radiation therapy. Int J Radiat Oncol Biol Phys 1980, 6:1573-1575.
38. Loeffler J.S., Harris J.R., Dahlberg W.K., Little J.B. Invitro radiosensitivity of human diploid fibroblasts derived from women with unusually sensitive clinical responses to definitive radiation therapy for breast cancer. Radiat Res 1990, 121:227-231.
39. Bentzen S.M. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother Oncol 1997, 43:121-131.
40. Bentzen S.M., Parliament M., Deasy J.O., et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys 2010, 76:S145-S150.
41. Bentzen S.M., Overgaard M., Overgaard J. Clinical correlations between late normal tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity. Eur J Cancer 1993, 29A:1373-1376.
42. Tucker S.L., Turesson I., Thames H.D. Evidence for individual differences in radiosensitivity of human skin. Eur J Cancer 1992, 28A:1783-1791.
43. Geara F.B., Peters L.J., Ang K.K., Wike J.L., Brock W.A. Radiosensitivity measurement of keratinocytes and fibroblasts from radiotherapy patients. Int J Radiat Oncol Biol Phys 1992, 24:287-293.
44. 0 and skin fibroblasts in log phase. Radiat Res 1990, 122:326-332.
45. Geara F.B., Peters L.J., Ang K.K., et al. Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose rate irradiation. Cancer Res 1992, 52:6348-6352.
46. Vozenin-Brotons M.C., Mauviel A. How to model the events in cutaneous fibrosis?. Med Sci (Paris) 2006, 22:172-177.
47. Meineke V., Müller K., Ridi R., et al. Development and evaluation of a skin organ model for the analysis of radiation effects. Strahlenther Onkol 2004, 180:102-108.
48. Fleckenstein J., Kühne M., Seegmüller K., et al. The impact of individual invivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011, 81:1465-1472.
49. Goutham H.V., Mumbrekar K.D., Vadhiraja B.M., et al. DNA double-strand break analysis by γ-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2012, 84:e607-e612.
50. Barcellos-Hoff M.H. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 1998, 150(5 Suppl.):S109-S120.
51. Stone H.B., Coleman C.N., Anscher M.S., McBride W.H. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003, 4:529-536.
52. Jobling M.F., Mott J.D., Finnegan M.T., et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res 2006, 166:839-848.
53. Li C., Wilson P.B., Levine E., et al. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int Cancer 1999, 84:155-159.
54. Mazeron R., Etienne-Mastroianni B., Pérol D., et al. Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer. Int Radiat Oncol Biol Phys 2010, 77:38-43.
55. Gossage L., Perry C., Abbotts R., Madhusudan S. Base excision repair factors are promising prognostic and predictive markers in cancer. Curr Mol Pharmacol 2012, 5:115-124.
56. Ozsahin M., Crompton N.E., Gourgou S., et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005, 11:7426-7433.
57. Schnarr K., Boreham D., Sathya J., Julian J., Dayes I.S. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys 2009, 74:1424-1430.
58. Finnon P., Kabacik S., MacKay A., et al. Correlation of invitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer. Radiother Oncol 2012, 105:329-336.
59. Chua M.L., Somaiah N., Bourne S., et al. Inter-individual and inter-cell type variation in residual DNA damage after invivo irradiation of human skin. Radiother Oncol 2011, 99:225-230.
60. Chua M.L.K., Somaiah N., Davies S., et al. Comparison of in vivo skin and in vitro blood lymphocyte models for the prediction of late normal tissue responses in breast radiotherapy patients. J Clin Oncol 2013, 31(suppl; abstr 11116).
61. Beaton L.A., Ferrarotto C., Marro L., et al. Chromosome damage and cell proliferation rates in invitro irradiated whole blood as markers of late radiation toxicity after radiation therapy to the prostate. Int J Radiat Oncol Biol Phys 2013, 85:1346-1352.
62. De Ruyck K., Van Eijkeren M., Claes K., et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and invitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005, 62:1140-1149.
63. Pantelias G.E., Terzoudi G.I. Astandardized G2-assay for the prediction of individual radiosensitivity. Radiother Oncol 2011, 101:28-34.
64. Brunt A.M., Sydenham M., Bliss J., et al. A5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015). EJC Supplements. Presidential sessions late breaking and best of ECCO 15-ESMO 34. Abstracts 2009, 7:2.
65. Khoo V.S., Dearnaley D.P. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer - the CHHiP trial. Clin Oncol (R Coll Radiol) 2008, 20:12-14.
66. Andreassen C.N., Alsner J., Overgaard M., Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003, 69:127-135.
67. Jeggo P., Lavin M.F. Cellular radiosensitivity: how much better do we understand it?. Int J Radiat Biol 2009, 85:1061-1081.
68. West C., Rosenstein B.S. Establishment of a radiogenomics consortium. Radiother Oncol 2010, 94:117-118.
69. Andreassen C.N. Searching for genetic determinants of normal tissue radiosensitivity -are we on the right track?. Radiother Oncol 2010, 97:1-8.
70. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006, 65:646-655.
71. Barnett G.C., Coles C.E., Burnet N.G., et al. No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol 2010, 97:9-14.
72. Talbot C.J., Tanteles G.A., Barnett G.C., et al. Areplicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy. Br J Cancer 2012, 107:748-753.
73. Peters L.J. The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol 1990, 17:177-190.